

U.S.A. 2015-2016

Transplantation Proceedings

An Official Publication of

The Transplantation Society

The Latin American Transplantation Society

The Japan Society for Transplantation

The European Society for Organ Transplantation

The British Transplantation Society

The Canadian Transplantation Society

The Transplantation Society of Australia and New Zealand

The Scandinavian Transplantation Society

EDITORIAL STAFF

Jean Dausset, European Editor,
Paris, France

David Anaise, Assistant Editor,
Stony Brook, N.Y.

Phillip R. Casson, Assistant Editor
New York, N.Y.

Felix T. Rapaport, M.D., Editor-in-Chief, *Stony Brook, N.Y.*

Radoslav J. Bachvaroff, Associate Editor,
Stony Brook, N.Y.

Robert J. Corry, Assistant Editor (Clinical)
Iowa City, Iowa

Wayne C. Waltzer, Assistant Editor (Abstracts)
Stony Brook, N.Y.

ADVISORY BOARD

Fritz Bach, *Minneapolis, Minn.*

Hans Balner, *Rijswijk, Holland*

J. Richard Batchelor, *England*

R. E. Billingham, *Dallas, Tex.*

Leslie Brent, *London, England*

Felix Cantarovich, *Buenos Aires, Argentina*

Raffaello Cortesini, *Rome, Italy*

Eli A. Friedman, *Brooklyn, N.Y.*

Robert A. Good, *Oklahoma City, Okla.*

Jean Hamburger, *Paris, France*

Milan Hasek, *Prague, Czechoslovakia*

George Klein, *Stockholm, Sweden*

H. Sherwood Lawrence, *New York, N.Y.*

H. M. Lee, *Richmond, Va.*

Richard R. Lower, *Richmond, Va.*

Robert McCluskey, *Boston, Mass.*

Sir Peter Medawar, *London, England*

John P. Merrill, *Boston, Mass.*

Felix Milgrom, *Buffalo, N.Y.*

Anthony P. Monaco, *Boston, Mass.*

John S. Najarian, *Minneapolis, Minn.*

G. J. V. Nossal, *Victoria, Australia*

Kendrick A. Porter, *London, England*

Keith Reemtsma, *New York, N.Y.*

Jorge Rodo, *Buenos Aires, Argentina*

Paul S. Russell, *Boston, Mass.*

Kenneth W. Sell, *Bethesda, Md.*

Maurice Slapak, *Portsmouth, England*

Thomas E. Starzl, *Pittsburgh, Pa.*

Paul Terasaki, *Los Angeles, Calif.*

Jules Traeger, *Lyon, France*

Dick V. Van Bekkum, *Rijswijk, Holland*

Jon J. Van Rood, *Leiden, Netherlands*

David W. Weiss, *Jerusalem, Israel*

Chester Zmijewski, *Philadelphia, Pa.*

ABSTRACTS EDITORIAL BOARD

Harold Atkins, *Stony Brook, N.Y.*

Clyde F. Barker, *Philadelphia, Pa.*

David Blumenstock, *Cooperstown, N.Y.*

Lewis Burrows, *New York, N.Y.*

C. B. Carpenter, *Boston, Mass.*

Karel A. Dicke, *Houston, Tex.*

Richard N. Fine, *Los Angeles, Calif.*

Henry Godfrey, *Valhalla, N.Y.*

Ronald D. Guttman, *Montreal, Canada*

Gail S. Habicht, *Stony Brook, N.Y.*

Mark A. Hardy, *New York, N.Y.*

George K. Kyriakides, *Miami, Fla.*

H. M. Lee, *Richmond, Va.*

Caliann T. Lum, *Hershey, Pa.*

Robert E. McCabe, *New York, N.Y.*

John C. McDonald, *Shreveport, La.*

Gerardo Mendez-Picon, *Richmond, Va.*

Frederick K. Merkel, *Chicago, Ill.*

Joshua Miller, *Miami, Fla.*

Kamal Mittal, *Bethesda, Md.*

Paul Nathan, *Cincinnati, Ohio*

Israel Penn, *Cincinnati, Ohio*

Herbert A. Perkins, *San Francisco, Calif.*

Robert R. Riggio, *New York, N.Y.*

Jerry C. Rosenberg, *Detroit, Mich.*

Leslie Rudolf, *Charlottesville, Va.*

E. A. Santiago-Delpin, *San Juan, Puerto Rico*

George W. Santos, *Baltimore, Md.*

D. P. Singal, *Ontario, Canada*

Sylvester Sterioff, *Rochester, Minn.*

Rainer Storb, *Seattle, Wash.*

William T. Stubenbord, *New York, N.Y.*

David E. R. Sutherland, *Minneapolis, Minn.*

Judith Thomas, *Greenville, N.C.*

Peter J. Tutschka, *Baltimore, Md.*

Paul Weiden, *Seattle, Wash.*

Horst Zincke, *Rochester, Minn.*

ACKNOWLEDGMENTS

The Local Organizing Committee acknowledges with gratitude the contributions of the following institutions:

Sandoz AG	Hospal
Sandoz BV	IBM Nederland
Stichting Algemene Loterij Nederland	IRE
Stichting Fondsenverwervingsacties	KLM
Volksgesondheid	Martinair Partyservice
Stöpler	Panchem
Ahold	Pharmacia Nederland
Amro Bank	Philips
Behring Instituut	Rhone-Poulenc Nederland
Biotest Pharma	Shell Nederland
Copex Air	Stichting Fondsenverwerving Militaire
Diacare	Oorlogs- en Dienstslichtoffers
Eli Lilly Nederland	Stichting 1940–1945
Fresenius	Travenol
Gambro	Universitaire Boekhandel Nederland
Greiner	Wellcome
Hoechst Pharma	

The Minister of Housing, Physical Planning and Environment and the Director and Staff of the Government Building Agency are gratefully acknowledged for their kind permission and personal help in organizing the symposium in the Ridderzaal Complex, as are the Burgomaster and Aldermen of The Hague for their hospitality.

Special indebtedness goes to Professor G. J. Tammeling and Dr. J. F. Ph. Hers for their advice and actual support in preparing the symposium, and to Ed Luinstra (Stöpler) and Carel Zorg Studio B. V. for their much appreciated and professional assistance.

The enthusiastic cooperation of Jacqueline Algera, Alimieke Bol, Renée Cortel, Verena Diepenveen, Marianne Franzen, Cathy Fung-Kim, Margaret Groenewegen, Els Hoekstra, Astrid Pomès, Hella van Welij, and the students working within the Eurotransplant Foundation has been the basis for the success of the symposium, and is gratefully acknowledged.

Transplantation Proceedings

An Official Publication of

The Transplantation Society

The Latin American Transplantation Society

The Japan Society for Transplantation

The European Society for Organ Transplantation

The British Transplantation Society

The Canadian Transplantation Society

The Transplantation Society of Australia and New Zealand

The Scandinavian Transplantation Society

VOL. XVI, NO. 3

JUNE 1984

CONTENTS

Preface..... *R. van Schilfgaarde, G. G. Persijn, and D. E. R. Sutherland* 565

GENERAL INTRODUCTION

Comprehensive Care Essential to Success in Diabetic Nephropathy*E. A. Friedman* 569

Biological Basis for Organ Transplantation in Diabetics.....*J. S. Najarian*
and D. E. R. Sutherland 573

Patient Selection and Risk Factors in Organ Transplantation in Diabetics: Experience
With Kidney and Pancreas*J. Traeger, J. M. Dubernard, E. Bosi,*
P. M. Piatti, A. Gelet, S. El Yafi, H. Betuel, A. Secchi, J. L. Touraine,
and G. Pozza 577

The Contribution of Pancreatic Transplantation to Current Concepts in Diabetes
K. F. Federlin and R. G. Bretzel 583

What to Expect From Pancreas Transplantation..... *P. McMaster* 587

Pancreas and Islet Transplant Registry Statistics..... *D. E. R. Sutherland* 593

Clinical Results of Renal Transplantation in Diabetic Patients*J. Jervell,*
B. O. Dahl, P. Fauchald, T. Moen, G. Sjødal, and A. Flatmark 599

Coronary Artery Disease in 100 Diabetics With End-Stage Renal Failure
W. E. Braun, D. F. Phillips, D. G. Vidt, A. C. Novick, S. Nakamoto,
K. L. Popowniak, E. Paganini, M. Magnusson, M. Pohl, D. R. Steinmuller,
D. Protiva, and C. Buszta 603

Natural History of Chronic Renal Failure in Juvenile Diabetes Mellitus
L. A. Castro, G. Hillebrand, R. Landgraf, W. Land, and H. J. Gurland 608

Selection and Assessment of Diabetic Patients for Dialysis and Transplant Programs
J. Michael, D. Adu, P. McMaster, J. H. Turney, and O. M. Gibby 611

Does Insulin-Dependent Diabetes Mellitus Still Increase Risk to Cadaveric Kidney
Transplantation? *L. H. Toledo-Pereyra, J. Whitten, S. Baskin, L. McNichol,*
W. Lin, and K. Thavarajah 613

(Continued)

CONTENTS

(continued)

Influence of Selection and Pretransplant Monitoring on Outcome of Renal Grafting in Diabetics.....	<i>H. Bryneger, O. Larsson, I. Ahlmén, P.-O. Attman, I. Blohmé, B. Frisk, and G. Nyberg</i>	615
Improving Results in Primary Diabetic Renal Transplantation	<i>H. Zincke, D. E. Engen, S. Sterioff, M. W. McDonald, P. P. Frohnert, and W. J. Johnson</i>	617
Cadaveric Renal Transplantation in Insulin-Dependent Diabetes Mellitus: Experience in the Canadian Multicentre Trial	<i>The Canadian Multicentre Transplant Study Group</i>	621
Improved Results of Renal Transplantation in Diabetic Nephropathy	<i>H. Wilczek, R. Gunnarsson, G. Lundgren, and L. Öst</i>	623
DR-Matching for Cadaveric Renal Transplants in Insulin-Dependent Diabetic Patients.....	<i>B. A. Vanderwerf and L. J. Koep</i>	628
Results of Renal Transplantation in Diabetics at the University of Minnesota Since 1979, Including a Comparison of Outcome in Diabetic and Nondiabetic Recipients Randomized to Cyclosporine Versus Azathioprine for Immunosuppression.....	<i>D. E. R. Sutherland, D. S. Fryd, M. Strand, N. Ascher, R. L. Simmons, and J. S. Najarian</i>	629
Diabetic Renal Allograft Recipient Pretreatment With Donor-Specific Blood Products and Concomitant Azathioprine Immunosuppression	<i>C. B. Anderson, G. A. Sicard, J. D. Tyler, G. E. Rodey, C. K. Anderman, and E. E. Etheredge</i>	633
Cadaveric Kidney Transplantation in Diabetics After Total Lymphoid Irradiation (TLI)	<i>Y. Vanrenterghem, M. Waer, K. Ang, E. van der Schueren, J. Gruwez, R. Bouillon, and P. Michielsen</i>	636
Conversion From Conventional Immunosuppression to Cyclosporine A Therapy in Diabetic Recipients of Cadaveric Kidney Transplants.....	<i>G. Thiel, R. Loertscher, F. P. Brunner, U. Keller, J. Landmann, M. Mihatsch, and F. Harder</i>	640
The Use of Intravenous Insulin in the Treatment of Diabetes During Rejection Episodes	<i>R. O'Donovan, P. Devlin, D. Bennet-Jones, V. Parsons, M. Bewick, M. Weston, and P. J. Watkins</i>	643
Left Ventricular Function Before and After Renal Transplantation in Diabetics	<i>O. Larsson, J. Wikstrand, P.-O. Attman, and I. Wallentin</i>	645
Recurrence of Diabetic Nephropathy in Human Renal Allografts: Preliminary Report of a Biopsy Study.....	<i>S. O. Bohman, H. Wilczek, G. Jaremko, and G. Lundgren</i>	649
Living Related Donors in Kidney Transplantation of Diabetics: A Five- to 12-Year Follow-Up Study	<i>P. P. Frohnert, C. F. Anderson, D. E. Engen, H. Zincke, and J. P. Vogel</i>	654
The Elderly Living Related Donor in Diabetic Renal Transplantation	<i>P.-O. Attman, I. Blohmé, H. Gäbel, H. Herlitz, O. Larsson, and H. Bryneger</i>	656

(Continued)

CONTENTS

(continued)

PANCREAS TRANSPLANTATION IN THE TREATMENT OF DIABETES

Selected Issues of Importance in Clinical Pancreas Transplantation	<i>D. E. R. Sutherland</i>	661
The Importance of Myocardial Imaging as a Selection Criterion of Patients Prior to Pancreas Transplantation	<i>L. H. Toledo-Pereyra</i>	671
Combined Renal and Segmental Pancreatic Transplantation as Part of an Integrated Program for the Treatment of Diabetic Renal Failure.....	<i>J. Michael, J. H. Turney, P. McMaster, D. Adu, and O. M. Gibby</i>	675
The Need for Pretransplant Pathologic Examination in Cadaver Donor Segmental Pancreas Transplantation	<i>J. P. Squifflet, J. Rahier, Y. Pirson, B. Vandeleene, M. Carlier, and G. P. J. Alexandre</i>	677
Procurement and Preservation of Human Pancreatic Grafts	<i>G. Lundgren, H. Wilczek, G. Klintmalm, G. Tydén, and C. G. Groth</i>	681
The Technique of Neoprene Injection for Human Pancreatic Transplantation: Experience in 40 Cases.....	<i>J. M. Dubernard, J. Traeger, E. Bosi, A. Gelet, S. El Yafi, A. Secchi, P. M. Piatti, A. M. Ruitton, J. L. Touraine, and G. Pozza</i>	684
Follow-Up of Simultaneous Kidney and Pancreas Transplantation in Type I Diabetes	<i>R. Landgraf, M. M. C. Landgraf-Leurs, D. Burg, A. Kampik, and W. Land</i>	687
Clinical Experience With Segmental Pancreatic Allografts.....	<i>R. Munda, M. R. First, C. Webb, and J. W. Alexander</i>	692
Minnesota Experience With 81 Pancreas Transplants Since 1978	<i>D. E. R. Sutherland, P. L. Chinn, F. C. Goetz, B. A. Elick, and J. S. Najarian</i>	695
Combined Kidney and Pancreas Grafting—Is it Really Safe and Does it Jeopardize the Kidney?	<i>P. McMaster, J. Michael, D. Adu, O. M. Gibby, T. Vlassis, and J. Turney</i>	704
Influence of Steroid Administration on the Endocrine Function of Neoprene-Injected Segmental Pancreas Allografts	<i>G. Pozza, A. Secchi, A. E. Pontiroli, E. Bosi, J. Traeger, J. M. Dubernard, A. Gelet, and J. L. Touraine</i>	707
Deterioration in Glucose Metabolism in Pancreatic Transplant Recipients After Conversion From Azathioprine to Cyclosporine.....	<i>R. Gunnarsson, G. Klintmalm, G. Lundgren, G. Tydén, H. Wilczek, J. Östman, and C. G. Groth</i>	709
Postoperative Management After Simultaneous Segmental Pancreas and Kidney Transplantation	<i>F. P. Lenhart, K. Unertl, U. Jensen, R. Landgraf, and W. Land</i>	713
Laboratory Findings During Rejection of Segmental Pancreatic Allografts	<i>G. Tydén, G. Lundgren, R. Gunnarsson, J. Östman, and C. G. Groth</i>	715

(Continued)

CONTENTS

(continued)

Clinical Aspects of Pancreatic Rejection in Pancreatic and Pancreaticorenal Allografts	<i>J. Traeger, J. M. Dubernard, P. M. Piatti, E. Bosi, A. Gelet, S. El Yafi, H. Betuel, A. Secchi, J. L. Touraine, and G. Pozza</i>	718
Indium-111 Labeled Platelets in Monitoring Pancreatic Transplants in Humans <i>W. A. Jurewicz, J. A. C. Buckels, J. G. A. Dykes, B. K. Gunson, R. J. Hawker, S. T. Chandler, C. N. McCollum, and P. McMaster</i>		720
Segmental Pancreatic Transplantation With Duct Ligation or Enteric Diversion: Technical Aspects.....	<i>C. G. Groth, G. Lundgren, H. Wilczek, G. Klintmalm, G. Tydén, R. Gunnarsson, and J. Östman</i>	724
Experience With 13 Segmental Pancreas Transplants in Cyclosporine-Treated Diabetic Patients Using Ethibloc for Duct Obliteration (Surgical Aspects) <i>W. Land, W.-D. Illner, D. Abendroth, and R. Landgraf</i>		729
Pathologic Evidence of Chronic Pancreatitis in Polymer Duct-Occluded Segmental Pancreas Allografts	<i>L. H. Toledo-Pereyra</i>	733
Intraductal Injection of Neoprene to Suppress Native Pancreatic Exocrine Secretion in Humans: Clinical and Metabolic Evaluation <i>V. Di Carlo, R. Chiesa, A. E. Pontiroli, G. Pozza, M. Carlucci, C. Staudacher, A. Secchi, and M. Cristallo</i>		736
Pancreatic Endocrine Function After Duct Occlusion in Humans.....	<i>I. B. Brekke, A. Bergan, L. Heen, and A. Flatmark</i>	739
Insulin, C-Peptide, Glucagon, and Somatostatin Secretion in Segmental Pancreatic Autotransplantation	<i>F. Fallucca, R. Tersigni, L. Giangrande, P. del Balzo, D. Zicari, M. Marinelli, G. Pimpinella, G. Ghirlanda, and S. Stipa</i>	741

EXPERIMENTAL PANCREAS TRANSPLANTATION

Advantage of Exocrine Drainage on Long-Term Endocrine Function in the Transplanted Rat Pancreas.....	<i>N. P. Ingram, M. S. Nolan, N. J. Lindsey, P. F. Boyle, A. Herold, S. Beck, D. N. Slater, and M. Fox</i>	747
Clinical and Experimental Experience With Pancreaticocystostomy for Exocrine Pancreatic Drainage in Pancreas Transplantation	<i>H. W. Sollinger, K. Cook, D. Kamps, N. R. Glass, and F. O. Belzer</i>	749
Effects of Intraductal Irradiation on the Canine Pancreas	<i>J. L. Faure, B. Provensal, J. M. Dubernard, X. Martin, M. Devonec, J. Margonari, and J. Traeger</i>	752
Different Techniques of Duct Occlusion for Experimental Pancreas Transplantation in Dogs	<i>H. Lippert, H. Wolff, D. Lorenz, O. Abri, and F. Kühn</i>	755
Duct Management of Segmental Pancreatic Allografts in Pigs <i>R. T. Schweizer, B. A. Sutphin, P. F. Pfau, R. D. Calaluze, and M. M. Berman</i>		756

(Continued)

CONTENTS

(continued)

Somatostatin: Progress in Segmental Pancreas Transplantation? An Experimental Study of Canine Duct-Occluded Grafts.....	<i>E. Steiner, R. Landgraf, W. Land, P. Gruner, H. Schneeberger, M. Stangl, W. Steimer, and H. Arnholdt</i>	760
Late Observations on Canine Segmental Pancreatic Autografts.....	<i>R. G. Cutfield, G. K. Kyriakides, L. Olson, R. M. Condie, D. H. Mintz, and J. Miller</i>	762
Prognosis of Experimental Pancreatic Transplantation in Relation to Vascular Reconstructive Procedure	<i>I. Vaněk, V. Bartoš, and V. Kočandrle</i>	764
Long-Term Endocrine Function of In Situ and Autografted, Duct-Obliterated Canine Left Pancreatic Segments	<i>H. G. Gooszen, R. van Schilfgaarde, M. Frölich, G. F. Cramer-Knijenburg, and M. P. M. van der Burg</i>	766
Effect of Venous Drainage to the Vena Cava and Denervation on Endocrine Function of Pancreatic Segments in Dogs	<i>D. Baumgartner, R. Illig, and D. E. R. Sutherland</i>	769
Comparison of Endocrine Function Between Right and Left Pancreas Autografts in Dogs...	<i>Y. Motoki, M. Gotoh, M. Monden, O. Sakane, K. Shima, and J. Okamura</i>	773
An Analysis of Long-Term Histologic Changes Leading to Decreased Endocrine Function After Duct Obliteration of the Canine Pancreas	<i>H. G. Gooszen, F. T. Bosman, and R. van Schilfgaarde</i>	776
Evidence for a Differential Importance of MHC and Non-MHC Alloantigens in Pancreas and Heart Transplantation in the Rat	<i>J. Klempnauer, L. Hoins, B. Steiniger, E. Günter, K. Wonigeit, and R. Pichlmayr</i>	778
Early Detection of Rejection in the Allografted Pancreas	<i>M. Gotoh, M. Monden, Y. Motoki, O. Sakane, K. Shima, and J. Okamura</i>	781
Histology of Rejection in Rat Pancreas Allografts With Suppressed or Preserved Exocrine Function	<i>B. Steiniger, J. Klempnauer, U. Brüsck, and K. Wonigeit</i>	783
Diagnosis of Early Pancreas Allograft Rejection With Indium-111-Oxine-Labeled Platelets ...	<i>H. W. Sollinger, L. M. Lieberman, D. Kamps, T. Warner, and K. Cook</i>	785
Fine Needle Biopsy of Canine Pancreas Graft: An Attempt at Cytologic Diagnosis in Graft Rejection	<i>E. Steiner, C. Hammer, W. Land, P. Gruner, H. Schneeberger, M. Stangl, and W. Steimer</i>	789
The Effect of Cyclosporine on the Survival of Pancreatic Allografts in Pancreatectomized Baboons	<i>D. F. du Toit, J. J. Heydenrych, G. Louw, T. Zuurmond, I. Laker, D. Els, S. Wolfe-Coote, A. Weidman, and H. Davids</i>	791
The Course of Pancreatic Allografts With Physiologic Secretion Drainage in Rats Temporarily Treated With Cyclosporine A	<i>W. Timmermann, T. Schang, and W. Thiede</i>	794

(Continued)

CONTENTS

(continued)

- Infection as a Complication of Roux-En-Y-Loop Jejunal Draining Rat Pancreas
Grafts, Including the Effect of Cyclosporine A
*N. J. Lindsey, N. P. Ingram, M. S. Nolan, P. F. Boyle, A. Herold, S. Beck,
A. Clark, D. N. Slater, and M. Fox* 797
- Effect of Theophylline in Experimental Pancreas Allotransplantation in Rats
A. Marni, M. E. Ferrero, and C. Rugarli 799
- The Effect of Prednisone and Azathioprine on the Endocrine Function of Canine
Segmental Pancreatic Autografts
*R. van Schilfgaarde, H. G. Gooszen, M. Frölich, G. F. Cramer-Knijnenburg, and
M. P. M. van der Burg* 802
- Segmental Pancreatic Allograft Survival in Pancreatectomized Baboons Treated With
Total Body or Lymphoid Irradiation and Perioperative Blood Transfusions
*D. F. du Toit, J. J. Heydenrych, B. Smit, T. Zuurmond, G. Louw, L. Laker,
D. Els, S. Wolfe-Coote, J. A. van der Merwe, and A. W. Groenewald* 804
- Hypothermic Preservation of the Rat Pancreas With A View to Maintaining
Endocrine Function Using Either Cold Storage or Pulsatile Perfusion
M. S. Nolan, N. J. Lindsey, N. P. Ingram, A. Herold, D. N. Slater, and M. Fox 807
- Effect of 24-Hour Cold Storage on the Histology and Long-Term Endocrine Function
of Autografted Canine Left Pancreatic Segments
*R. van Schilfgaarde, H. G. Gooszen, F. T. Bosman, M. Frölich,
G. F. Cramer-Knijnenburg, and M. P. M. van der Burg* 809

TRANSPLANTATION OF PANCREATIC ISLET CELLS

- Current Status of Experimental Islet Transplantation
K. J. Lafferty, S. J. Prowse, C. J. Simeonovic, O. Hegre, and H. P. Chase 813
- Clinical Feasibility of Islet Transplantation.....*D. W. Scharp* 820
- Potential Cases of Normal Islet Autotransplantation in Humans
J. J. Altman, D. Houlberg, F. Bruzzo, N. Desplanque, J. Boillot, and F. E. Dazza 826
- Islet Cell Autotransplantation: Risks, Complications, and Long-Term Follow-Up
L. H. Toledo-Pereyra 829
- The Metabolic Effects of Islet Transplantation in the Diabetic Dog
D. Alderson and J. R. Farndon 831
- Intrasplenic Isografts of Canine Pancreatic Islets: Metabolic Study
R. V. Rajotte, G. L. Warnock, A. W. Procyshyn, and K. Wiczorek 834
- Effect of Streptozotocin on Composite Graft Survival
H. Reece-Smith, B. J. Fairbrother, P. McShane, and P. J. Morris 838

(Continued)

CONTENTS

(continued)

Islet Transplantation in Rats: Secondary Complications and Pancreatic Insulin Content	<i>W. Arendarczyk, C. Wójcickowski, and B. Pankowska</i>	840
Cryopreservation and Transplantation of Organ-Cultured Fetal Islets	<i>T. E. Mandel and W. M. Carter</i>	842
Islet Transplantation in Autoimmune Diabetes Mellitus	<i>C. Weber, W. Ting, K. Rosenkrantz, S. Rivera, B. Pernis, and K. Reemtsma</i>	845
Xenotransplantation of Human Fetal Islets in Nude Mice	<i>T. E. Mandel and H. M. Georgiou</i>	849
Evidence that Major Histocompatibility Complex Restriction is Involved in the Survival of Cultured Endocrine Allografts in Mice	<i>S. T. Bartlett, A. Naji, W. K. Silvers, and C. F. Barker</i>	851
T-Cell Reactions Versus Kidney Cells, Islets of Langerhans, and Non-T Lymphocytes	<i>D. Roth, T. Russell, L. Fuller, G. K. Kyriakides, D. Mintz, and J. Miller</i>	854
Reactivity of Pancreas Islet Cells With Antisera of Known Specificity	<i>K. Ulrichs, T. Schang, R. Keller, and W. Müller-Ruchholtz</i>	857
Effect of Pretreatment of Isolated Adult Islets With Monoclonal Antibody	<i>H. Reece-Smith, P. McShane, and P. J. Morris</i>	861
Islet Allografts in Rats Made Tolerant of Renal Allografts by Whole Blood Transfusion Compared to Islet Allografts After Blood Transfusion Alone	<i>D. W. R. Gray, A. D. Hibberd, P. McShane, and P. J. Morris</i>	863
Prolongation of Rat Islet Allografts With the Use of Ultraviolet Irradiation, Without Immunosuppression.....	<i>M. A. Hardy, H. Lau, and K. Reemtsma</i>	865
The Survival of Isolated Pancreatic Islets in Rats Rendered Immunologically Unresponsive to Renal Allografts	<i>D. W. R. Gray, H. Reece-Smith, B. Fairbrother, P. McShane, and P. J. Morris</i>	870
Combined Liver and Pancreatic Islet Allotransplantation	<i>H. Reece-Smith, G. Muller, P. McShane, and P. J. Morris</i>	872

THIRD INTERNATIONAL SYMPOSIUM ON HEART SUBSTITUTION

Perspectives On Heart Substitution.....	<i>R. Cortesini</i>	877
Future of Cardiac Transplantation.....	<i>D. A. Cooley</i>	880
Clinical Trials of Two-Stage Cardiac Transplantation Using an Orthotopic Mechanical Heart	<i>D. A. Cooley</i>	882
Heterotopic Versus Orthotopic Heart Transplantation	<i>C. N. Barnard and D. K. C. Cooper</i>	886

(Continued)

CONTENTS

(continued)

Approaches to the Artificial Heart <i>G. Jacobs, H. Harasaki, R. Kiraly, L. Golding, and Y. Nose</i>	893
Artificial Heart Substitution: The Total or Auxiliary Artificial Heart <i>J. Kolff</i>	898
Current Status of Research and Development of Artificial Hearts in Japan .. <i>K. Atsumi</i>	908
Past, Present, and Future of Mechanical Circulatory Support..... <i>J. T. Watson</i>	918

Experience With 13 Segmental Pancreas Transplants in Cyclosporine-Treated Diabetic Patients Using Ethibloc for Duct Obliteration (Surgical Aspects)

W. Land, W.-D. Illner, D. Abendroth, and R. Landgraf

SINCE August 1979, 18 segmental pancreas transplantations in 17 diabetic recipients with end-stage renal failure have been performed at our institution (17 combined pancreatic and renal allotransplantations, one pancreatic retransplantation). The course and outcome of simultaneous pancreatic and renal transplantations in the first three patients receiving conventional immunosuppressive therapy have been published elsewhere.¹⁻³ This article presents our experience with 13 segmental pancreatic allotransplantations in 12 patients treated with the new immunosuppressive agent cyclosporine (Sandimmune, Sandoz Ltd., Basel, Switzerland). As details of patient selection, postoperative management, and long-term follow-up are presented by our group elsewhere in this issue,^{4,5} we will mainly concentrate on surgical aspects in this report.

MATERIALS AND METHODS

Twelve type I diabetic patients in end-stage renal failure (aged 25 to 49 years) have been accepted for treatment. Combined pancreatic and renal allotransplantation was performed in all 12 patients, pancreatic retransplantation alone in one patient.

Donor Pancreatectomy

The technique of pancreas harvesting has been described previously.² Recently, we modified our technique slightly: (1) Hypothermic in situ perfusion of the pancreas with Euro-Collins' solution was provided by an intraaortally situated catheter via the celiac axis. (2) The celiac axis, including an aortal patch and the portal vein, respectively, were used for anastomosis exclusively. Harvesting of the pancreas was combined with the removal of the kidneys (all cases), the removal of the heart (three cases), and the removal of heart/lung (one case). Organ harvesting was performed either at our own clinic or at external hospitals. Transportation of the organs was provided by helicopters or emergency cars. Cold ischemia time never exceeded five and one half hours.

Special Donor Criteria

Special donor criteria for pancreas harvesting were used at our institution: age, 15 to 40 years; stable circulation; blood sugar and serum amylase, normal/subnormal; no obesity; negative crossmatch; and blood group compatibility.

Duct Obliteration

The duct obliteration procedure was started immediately before transplantation; under hypothermic in vitro conditions, the duct was cannulated (Abbocath cannula). Between 3.5 and 6 mL of Ethibloc (prolamine, alcoholic amino acid solution) were injected throughout the ductal system under x-ray control. Duct obliteration was considered to be efficient when first signs of overinjection appeared as revealed by x-ray. After occlusion, the ductal orifice, as well as the parenchyma near the cut surface, were ligated.

Recipient Operation

Our technique of pancreatic transplantation has been slightly modified recently. The segmental pancreas graft was situated (in an upside-down position) extraperitoneally in the right iliac fossa by positioning the distal 2/3 intraperitoneally. Circulation was established by end-to-side anastomosis of the portal vein to the right external iliac vein and the celiac axis (plus patch) to the right external iliac artery. The wound was drained for two to four days either by a silicon rubber drain or Penrose drain (Fig. 1). Following closure of this wound, a renal graft from the same donor was placed in the left iliac fossa using the standard technique.

Immunosuppressive Protocol

Basic immunosuppression consisted of intravenous (IV) cyclosporine 3.5 to 5 mg/kg/d over the first ten days posttransplant. Cyclosporine was administered orally (15 mg/kg) until the end of one month, when it was decreased

From the Transplantation Center, Department of Surgery, Klinikum Grosshadern, and the Department of Internal Medicine "Innenstadt," University of Munich.

Address reprint requests to Professor Dr W. Land, Department of Surgery, Klinikum Grosshadern, Marchioninstr 15, D-8000 München 70, FRG.

© 1984 by Grune & Stratton, Inc.

0041-1345/84/1603-0044\$03.00/0



Fig. 1. Technique recently used in segmental pancreatic transplantation: partially extra/interperitoneal position of the graft. For anastomosis, the portal vein as well as the celiac axis (plus an aortal patch) are used. The operation is done at the right iliac fossa.

by 2 mg/kg monthly to a maintenance level of 6 to 8 mg/kg monthly to a maintenance level of 6 to 8 mg/kg body wt.

Steroids (methylprednisolone) were begun at 500 mg IV intraoperatively by decreasing the daily dose to 30 mg

Table 1. Results of Simultaneous Pancreatic and Renal Transplantation Under Cyclosporine Therapy (12 Patients)

Patients in the Consecutive Series (age)	Survival Time (mo)		
	Pancreas	Kidney	Patient
4. H. S.* (36 yr)	(Venous thrombosis)	27	27
5. P. K. (41 yr)	26	26	26
6. A. B. (33 yr)	16	16	16
7. G. L. (26 yr)	6	6	6
8. K. F. (49 yr)	1	1	1†
9. R. J. (25 yr)	2	2	6
	(Rejection)	(Rejection)	
10. H. K. (42 yr)	6	6	6
11. F. S. (40 yr)	5	5	5
12. U. S. (33 yr)	2	2	2
13. S. K. (27 yr)	(No function)	2	2
14. M. S. (36 yr)	1.5	1.5	1.5
15. G. S. (33 yr)	1	1	1

*Retransplantation: second occurrence of venous thrombosis.

†See Table 2, same patient.

during the first two weeks posttransplant. During the next two months, methylprednisolone was slowly decreased to a daily dose of 8 mg and maintained at that level.

Antirejection treatment. Antirejection treatment consisted of three IV bolus injections of 500 mg methylprednisolone during the first rejection episode. The second and third rejection episodes were treated by administration of antithymocyte globulin (ATG, Fresenius, Frankfurt, FRG) in a dose of 4 to 7.5 mg/kg daily over a period of seven days in combination with methylprednisolone in a dose of 120 mg IV daily until reversal.

RESULTS

The overall results of 12 combined pancreatic and renal transplantations (and one pancreatic retransplantation) are shown in Table 1. One patient died of acute liver failure (acute yellow liver necrosis) posttransplant. The other patients are currently alive. Eight of 13 pancreatic grafts, as well as ten of 12 renal grafts, are currently functioning (August 1983); pancreatic grafts after 26, 16, 6, 6, 5, 2, 1½, and 1 month; renal grafts 27, 26, 16, 6, 6, 5, 2, 2, 1½, and 1 month. Four of 13

Table 2. Early (Local) Complications Following Simultaneous Organ Transplantation

Patient	Complications	
	Pancreas	Kidney
4. H. S.	Venous thrombosis (twice)	None
5. P. K.	Transient fistula	Rupture after biopsy (led to operative repair)
6. A. B.	Peripancreatic fluid collection	Wound hematoma (led to evacuation)
7. G. L.	Transient fistula	Wound hematoma (led to evacuation)
8. K. F.	None	None
9. R. J.	Fistula; infection (rejection)	Rejection
10. H. K.	Peripancreatic fluid collection	None
11. F. S.	Peripancreatic fluid collection	Wound hematoma (led to evacuation)
12. U. S.	Transient fistula	None
13. S. K.	No function: infection (led to exploration)	Distal ureter necrosis (led to operative repair)
14. M. S.	Fistula	None
15. G. S.	None	None

pancreatic grafts failed because of acute irreversible vascular rejection,¹ acute posttransplant venous thrombosis,² and no primary function.¹ Concerning the last case, an abnormal blood supply of the body and tail of the donor pancreas has to be discussed (only a few nutritive branches arising from the splenic artery without any parenchyma presentation were shown by angiography). We observed a relatively high incidence of early postoperative local complications on both sites of the grafts as shown in Table 2. At the site of the pancreatic graft, peripancreatic fluid collection requiring repeated needle aspiration and transient pancreatic fistula, respectively, were encountered most frequently; at the site of the renal graft, deep wound hematomas requiring surgical evacuation was observed.

Rejection episodes of both organs proved to be almost mild under cyclosporine treatment. There was only one acute vascular-type rejection not responding to antirejection treatment. Normally, all rejection episodes could be reversed either by methylprednisolone (IV bolus) alone or by combined administration of methylprednisolone and ATG.

DISCUSSION

Our current technique of combined segmental pancreatic and renal grafting using cyclosporine as posttransplant immunosuppressant has been associated with (1) low mortality, (2) an acceptable morbidity, (3) rare immunologic graft loss, (4) a relatively high incidence of early local complications, and (5) a reasonable rate of functioning pancreatic grafts (at the present time, August 1983: 61.5%).

We assume and discuss that this high rate of functioning pancreatic grafts is primarily a result of the strong immunosuppressive potency of the new agent cyclosporine, which reduces the events of irreversible allograft rejection. This observation is in accordance with our results obtained in cadaveric renal transplantation using cyclosporine as basic immunosuppressive therapy; the one-year graft survival rate of renal allografts has

improved by 20% (to 80%) compared with our historic controls using conventional immunosuppressive therapy.⁶

The clinical use of cyclosporine may also have led to the low rate of mortality in our recent series, although other contributing factors, such as better selection and improved management of the patients, and the gaining of experience within the transplant group may play some role.

The morbidity observed in our patients after combined transplantation certainly is higher than in kidney-transplanted patients but it seems acceptable. This morbidity mainly concerns the incidence of early local complications such as peripancreatic fluid collection and transient pancreatic fistula at the site of the pancreatic graft, as well as severe wound hematomas at the site of the renal graft.

Indeed, the incidence of complications from residual function of the exocrine system of the duct-occluded pancreatic graft worries us. We believe that these local complications probably arise from a too-early reabsorption of the occlusion substance Ethibloc (Ethicon, Raritan, NJ) before the acini are completely atrophied (a decisive difference between Ethibloc and neoprene used by the Lyon group and others). It is worthwhile to mention that the administration of somatostatin did not prevent these local complications from arising from residual exocrine secretion. On the other hand, this property of early reabsorption may be the reason for the good long-term function of the pancreatic grafts as discussed by us elsewhere in this issue.⁴ If it is suggested that a remaining foreign body causes increased fibrosis in the graft over a longer period of time, then the early reabsorption of ethibloc would imply a beneficial effect (as far as long-term function is concerned) because of a milder fibrosis-inducing effect. A completely intraperitoneal position of Ethibloc-occluded pancreatic grafts might reduce this kind of local complication.

The incidence of wound hematoma at the site of the renal graft is obviously a result of

our aggressive regimen of early postoperative anticoagulation (heparinization). This protocol was applied to prevent venous thrombosis of the splenic vein of the pancreatic graft. In fact, this complication can be prevented completely by aggressive anticoagulation therapy according to our experience. Nevertheless, a

new therapeutic concept of posttransplant anticoagulation is being worked out at the present time.

ACKNOWLEDGMENT

We thank Mrs B. König for preparing the manuscript.

REFERENCES

1. Land W, Weitz H: *Lancet* 2:1131, 1973
2. Land W, Liebe S, Höpp H, et al: *Chir Praxis* 27:15, 1980
3. Landgraf R, Abendroth D, Land W: *Horm Metab Res [Suppl]* 13:67, 1983
4. Landgraf R, Landgraf-Leurs MMC, Burg D, et al: (This issue)
5. Lenhard FP, Unertl K, Jossen V, et al: (This issue)
6. Land W, Castro LA, Günther K, et al: *Transplant Proc* 15:2517, 1983